Driving CAR T cells towards dermatologic oncology

Area of Science:

• Immunotherapy
• Dermatologic Oncology
• Cellular Therapy

Background:

• Approximately 50% of metastatic melanoma patients benefit from combined immune checkpoint inhibition (ICI) targeting CTLA-4 and PD-1.
• Patients refractory to ICI require alternative treatment strategies, with chimeric antigen receptor (CAR) T-cell therapy showing promise.
• CAR T-cell therapy has faced challenges in solid tumors, including melanoma, necessitating strategies to overcome tumor escape.

Purpose of the Study:

• To investigate the feasibility of equipping a single T lymphocyte with two distinct tumor antigen-specific receptors.
• To explore novel therapeutic approaches for metastatic melanoma patients who do not respond to current treatments.
• To address mechanisms counteracting tumor escape in the context of CAR T-cell therapy for solid tumors.

Main Methods:

• Combined lentiviral transduction and RNA-electroporation methods were used to engineer T cells.
• The study focused on equipping the same T lymphocyte with two different tumor antigen-specific receptors.
• Feasibility of this dual-receptor engineering approach was assessed.

Main Results:

• Demonstrated the feasibility of a novel approach combining lentiviral transduction and RNA-electroporation.
• Successfully equipped the same T lymphocyte with two different tumor antigen-specific receptors.
• This dual-targeting strategy represents a potential advancement in CAR T-cell therapy.

Conclusions:

• The developed method for equipping T cells with dual antigen receptors is feasible.
• Further research is needed to optimize CAR T-cell therapy for melanoma, including antigen selection and enhancing T-cell potency.
• This strategy holds potential for improving outcomes in dermatologic oncology, pending further development and clinical translation.